Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
-5°
Clear
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
92.38
+0.04 (+0.04%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Gilead Sciences
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
35
36
Next >
$1000 Invested In This Stock 20 Years Ago Would Be Worth $10,000 Today
February 07, 2024
Via
Benzinga
2 Beaten-Down Dividend Stocks to Buy Hand Over Fist
February 07, 2024
These stocks aren't value traps.
Via
The Motley Fool
Late-Session Earnings Bonanza: Ford, Chipotle, Snap & More
February 06, 2024
The Dow gained +141 points, +0.37%, while the S&P gained +0.23%. The Nasdaq, while positive, was essentially flat at +0.07%, while the small-cap Russell won the day, +0.85%, and continues inching its...
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Gilead Sciences (GILD) Q4 2023 Earnings Call Transcript
February 06, 2024
GILD earnings call for the period ending December 31, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Why Gilead Sciences Stock Is Trading Lower After The Bell
February 06, 2024
Gilead Sciences shares are trading lower in Tuesday's after-hours session after the company reported weak earnings results and issued soft guidance.
Via
Benzinga
Gilead Rode An Unexpected Source For Its Sales Beat, But Profit Came Up Short
February 06, 2024
Gilead reported slightly better-than-expected fourth-quarter sales, while earnings and profit guidance lagged.
Via
Investor's Business Daily
Topics
Earnings
Exposures
Financial
Earnings Scheduled For February 6, 2024
February 06, 2024
Companies Reporting Before The Bell • BP (NYSE:BP) is projected to report quarterly earnings at $1.05 per share on revenue of $53.50 billion.
Via
Benzinga
Preview: Gilead Sciences's Earnings
February 05, 2024
Via
Benzinga
Behind the Scenes of Gilead Sciences's Latest Options Trends
January 25, 2024
Via
Benzinga
If You Invested $100 In This Stock 20 Years Ago, You Would Have $1,000 Today
January 23, 2024
Via
Benzinga
Tech Slides, Chinese Stocks Rebound, New York Community Bancorp Tumbles: What's Driving Markets Tuesday?
February 06, 2024
At noon trading in New York, major equity indices on Wall Street remain directionless as traders evaluate the future course of monetary policy ahead of several speeches by Federal Reserve officials in...
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
3 Top Pharma Stocks to Buy Now: February 2024
February 01, 2024
Discover why these three pharma stocks should be on your buy list in February 2024 - they could be your ticket to explosive portfolio growth.
Via
InvestorPlace
A New COVID-19 Variant Is Rapidly Spreading Around The Globe, Other Pandemic Threats Exist – What Are The Choices For Treatment?
January 31, 2024
Colds, flu and RSV aren't the only viral illnesses people have to worry about this winter. A new variant of COVID-19 is rapidly spreading, reminding the world of just how dangerous this virus is.
Via
Benzinga
Exposures
COVID-19
Pharma Giant Gilead Raises Stake In Cancer-Focused Arcus Biosciences, Stock Soars
January 30, 2024
Arcus Biosciences sees a 17.1% surge as Gilead Sciences amends collaboration, investing $320M at $21.00/share. Accelerate joint programs in cancer therapy.
Via
Benzinga
Roche Walks Away From HOOKIPA Pharma-Partnered KRAS-Focused Cancer Deal
January 29, 2024
HOOKIPA Pharma's strategic focus on HB-200 program for HPV16+ HNSCC, infectious disease cure collaboration with Gilead, and recent developments.
Via
Benzinga
Despite its impressive fundamentals, NASDAQ:GILD remains undervalued.
January 25, 2024
When you look at GILEAD SCIENCES INC (NASDAQ:GILD), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via
Chartmill
Gilead's Tecartus Dropped From FDA List Of CAR-T Therapy With Updated Label Warning Of "Risks Of Secondary Cancer'
January 24, 2024
FDA issues classwide black box warning for CAR-T therapies due to T-cell cancer risk. Drops Gilead's cell therapy from the list.
Via
Benzinga
Exposures
Product Safety
Focus On Bristol Myers, Gilead Sciences, Johnson & Johnson, Novartis: FDA To Issue Classwide Black Box Warning on CAR-T Therapies For Blood Cancer Treatment
January 23, 2024
In a significant development, the FDA is set to impose a classwide black box warning following its investigation into secondary T-cell cancers arising from the use of existing CAR-T therapies.
Via
Benzinga
Exposures
Product Safety
7 Speculative Stocks to Double Your Money THIS Year
January 22, 2024
Although terribly risky, these stocks to double your money could be enticing if you have some pocket change lying around.
Via
InvestorPlace
Momentum Shifts Back To Tech Stocks As Healthcare Lags In 2024
January 22, 2024
Small Cap traders are taking a break in 2024 as XBI is down 2.51% YTD.
Via
Talk Markets
Why Gilead Sciences Stock Got Mashed on Monday
January 22, 2024
A late-stage trial of an otherwise successful cancer drug failed to produce the desired results.
Via
The Motley Fool
S&P 500, Dow Extend All-Time Highs: 'It's A Lot Of Fun For Stock Investors While It Lasts,' Wall Street Veteran Says
January 22, 2024
Stock market continues upward trend, with all major indexes reaching record highs. Wall Street veteran Ed Yardeni outlines three possible scenarios.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Dow Gains Over 100 Points; Archer-Daniels-Midland Shares Plunge
January 22, 2024
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100 points on Monday. The Dow traded up 0.27% to 37,967.81 while the NASDAQ rose 0.31% to 15,358.70. The...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
S&P 500, Nasdaq, Dow Jones Strike All-Time Highs Ahead Of Key Earnings This Week: What's Driving Markets Monday?
January 22, 2024
US stocks rise to record highs on strong earnings reports, with small caps outperforming. Dollar steady, gold down, oil up. Bitcoin tumbles. AMD, TSLA, ADM, GILD, WDC top movers. GE, AAPL, FB, AMZN,...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why CommScope Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Session
January 22, 2024
Shares of CommScope Holding Company, Inc. (NASDAQ: COMM) fell sharply during Monday’s session. B of A Securities analyst Tal Liani downgraded CommScope from Neutral to Underperform and lowered the...
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
January 22, 2024
Via
Benzinga
Crude Oil Surges Over 2%; US Leading Economic Index Falls In December
January 22, 2024
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 150 points on Monday. The Dow traded up 0.41% to 38,018.23 while the NASDAQ rose 0.30% to 15,356.67. The S&P...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
Why Is HIV Drug Giant Gilead Stock Falling Monday?
January 22, 2024
Gilead's Phase 3 EVOKE-01 study on Trodelvy in metastatic non-small cell lung cancer didn't meet overall survival endpoint. Despite numerical OS improvement, further exploration is planned.
Via
Benzinga
Gilead Sciences Stock Crashes 9% After Cancer Drug Fails A Key Test
January 22, 2024
The company had hoped Trodelvy would extend overall survival for patients with a form of lung cancer.
Via
Investor's Business Daily
EXCLUSIVE: The 'Buy Everything' Market Is Over: Synopsys-Ansys Merger Provides Fertile Ground For This Stock Picker
January 18, 2024
The "buy everything" sentiment that powered equity indices higher last quarter is over. It's a stock picker's market, Marc Chaikin says.
Via
Benzinga
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
35
36
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.